Buscar
Mostrando documentos 1741-1750 de 1778
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by
vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine ...
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebocontrolled, phase 2 trial
Background This is the first randomised controlled trial for assessment of the immunogenicity and safety of a
candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate
dose ...
Virology, pathogenesis, diagnosis and in-line treatment of COVID-19
SARS-CoV-2, a newly emerged pathogen in December 2019, marked as one of the highly pathogenic Coronavirus, and altogether this is the third coronavirus attack that crossed the species barrier. As of 1st July 2020, it is ...
Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines
The coronavirus disease 2019 (COVID-19) pandemic caused by a novel coronavirus, SARSCoV-2, has infected more than 4.9 million individuals and resulted in over 300,000 deaths
globally. The rapid spread of the virus and the ...
Design of a peptide-based subunit vaccine against novel coronavirus SARSCoV-2
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China,
and has subsequently spread worldwide. In the absence of any antiviral or immunomodulatory therapies, the
disease ...
Vacunas contra el coronavirus
Es difícil aventurar cuándo se podrá disponer de vacunas
contra la infección por coronavirus SARS-CoV-2. La aparición de la COVID-19 ha hecho pensar en las vacunas como
la mejor manera de poder prevenirla, como ocurre ...
Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus
The global pandemic of coronavirus disease 2019 (COVID-19), caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in over 7,273,958 cases with almost over 413,372 deaths worldwide as ...
Advances in the possible treatment of COVID-19: A review.
The emergence of the global pandemic caused by novel severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) has put a challenge to identify or derive the therapeutics for its prevention and treatment. Despite ...
Current status of potential therapeutic candidates for the COVID-19 crisis
As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019) pandemic has swept through 213
countries and infected more than 1,870,000 individuals, posing an unprecedented threat to international health
and ...
COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses
The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China and
spread around the ...